{"nctId":"NCT00051636","briefTitle":"Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period","startDateStruct":{"date":"2001-01"},"conditions":["Paget's Disease of Bone"],"count":172,"armGroups":[{"label":"Zoledronic Acid and Placebo to Risedronate","type":"EXPERIMENTAL","interventionNames":["Drug: Zoledronic Acid","Drug: Placebo to Risedronate","Dietary Supplement: Calcium and Vitamin D"]},{"label":"Risedronate and Placebo to Zoledronic Acid","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Risedronate","Drug: Placebo to Zoledronic Acid","Dietary Supplement: Calcium and Vitamin D"]}],"interventions":[{"name":"Zoledronic Acid","otherNames":["Reclast, Aclasta"]},{"name":"Risedronate","otherNames":["Actonel"]},{"name":"Placebo to Risedronate","otherNames":[]},{"name":"Placebo to Zoledronic Acid","otherNames":[]},{"name":"Calcium and Vitamin D","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 30 years or older\n* Serum alkaline phosphatase (SAP) 2 times upper limit normal (ULN)\n* Confirmed diagnosis of Paget's disease of the bone (by x-ray, magnetic resonance imaging, computerized tomography, radioisotope imaging, etc.).\n* 90 days washout calcitonin\n* 180 day washout bisphosphonate\n\nExclusion Criteria:\n\n* Allergic reaction to bisphosphonates\n* History of upper gastrointestinal disorders\n* History of iritis, uveitis\n* Calculated creatinine clearance \\< 30 ml/min at baseline\n* Evidence of vitamin D deficiency\n\nOther protocol-defined inclusion/exclusion criteria applied.","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients Who Achieve Therapeutic Response at 6 Months.","description":"Therapeutic response is defined as a reduction of at least 75% from baseline (Visit 1) in total serum alkaline phosphatase excess (difference between measured level and midpoint to the normal range) or normalization of serum alkaline phosphatase at the end of six months.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"60","spread":null}]}]}]},{"type":"SECONDARY","title":"Relative Change in Serum Alkaline Phosphatase (SAP) in Units Per Liter (U/L) at Day 28","description":"The percent change in serum alkaline phosphatase from baseline to day 28 was measured.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-48.8","spread":"11.51"},{"groupId":"OG001","value":"-28.4","spread":"17.72"}]}]}]},{"type":"SECONDARY","title":"Relative Change in Serum C-telopeptide (CTx) in ng/mL at Day 10","description":"The percent change in serum C-telopeptide from baseline to day 10 was measured.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-85.4","spread":"18.00"},{"groupId":"OG001","value":"-36.7","spread":"69.58"}]}]}]},{"type":"SECONDARY","title":"Relative Change in Urine Alpha C-telopeptide (Î±-CTx) in ug/mmol at Day 10","description":"The percent change in urine alpha C-telopeptide from baseline to day 10 was measured.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-90.3","spread":"13.19"},{"groupId":"OG001","value":"-29.9","spread":"37.52"}]}]}]},{"type":"SECONDARY","title":"Time to First Therapeutic Response","description":"A therapeutic response was defined as a reduction of at least 75% from baseline (Visit 1) in serum alkaline phosphatase excess (difference between measured level and midpoint to the normal range) or normalization of serum alkaline phosphatase.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"78","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Who Achieved Serum Alkaline Phosphatase Normalization at Day 28 Relative to Baseline","description":"Normalization of serum alkaline phosphatase occurred if the serum alkaline phosphatase measurement fell within the normal range.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Pain Severity Score","description":"Change in pain severity score from Brief Pain Inventory-Short Form (BPI-SF). This scale values are 0 to 10, a lower score means little to no pain while a higher score means greater pain.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"1.77"},{"groupId":"OG001","value":"-0.7","spread":"2.22"}]}]}]},{"type":"SECONDARY","title":"Change in Pain Interference Score","description":"Change in pain interference score from Brief Pain Inventory-Short Form (BPI-SF). This scale values are 0 to 10, a lower score means little to no pain while a higher score means greater pain.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"1.97"},{"groupId":"OG001","value":"0.1","spread":"1.72"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Loss of Therapeutic Response During the Extended Observation Period","description":"Extended observation period. A therapeutic response is defined as a reduction of at least 75% from baseline in serum alkaline phosphatase excess or normalization of serum alkaline phosphatase.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Partial Disease Relapse During the Extended Observation Period","description":"Extended observation period. A partial disease relapse was defined as an increase in serum alkaline phosphatase \\>= 50% from the serum alkaline phosphatase measurement at month 6 and at least 1.25 times the upper normal limit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Disease Relapse During the Extended Observation Period","description":"Extended observation period. A disease relapse was defined as the occurrence of a serum alkaline phosphatase level that was \\>= 80% of baseline serum alkaline phosphatase value.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":89},"commonTop":["Arthralgia","Headache","Nausea","Nasopharyngitis","Pain in extremity"]}}}